[go: up one dir, main page]

CY1113334T1 - Ενωσεις, συνθεσεις και χρησεις παραγωγων βενζοθειαζολης - Google Patents

Ενωσεις, συνθεσεις και χρησεις παραγωγων βενζοθειαζολης

Info

Publication number
CY1113334T1
CY1113334T1 CY20121101106T CY121101106T CY1113334T1 CY 1113334 T1 CY1113334 T1 CY 1113334T1 CY 20121101106 T CY20121101106 T CY 20121101106T CY 121101106 T CY121101106 T CY 121101106T CY 1113334 T1 CY1113334 T1 CY 1113334T1
Authority
CY
Cyprus
Prior art keywords
compounds
compositions
disease
benzothiesol
producers
Prior art date
Application number
CY20121101106T
Other languages
Greek (el)
English (en)
Inventor
William E Klunk
Jr Chester A Mathis
Yanming Dr Wang
Original Assignee
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/388,173 external-priority patent/US7270800B2/en
Priority claimed from US10/645,847 external-priority patent/US20050043523A1/en
Application filed by University Of Pittsburgh - Of The Commonwealth System Of Higher Education filed Critical University Of Pittsburgh - Of The Commonwealth System Of Higher Education
Publication of CY1113334T1 publication Critical patent/CY1113334T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CY20121101106T 2003-03-14 2012-11-16 Ενωσεις, συνθεσεις και χρησεις παραγωγων βενζοθειαζολης CY1113334T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/388,173 US7270800B2 (en) 2000-08-24 2003-03-14 Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US10/645,847 US20050043523A1 (en) 2003-08-22 2003-08-22 Benzothiazole derivative compounds, compositions and uses
EP04720788A EP1611115B1 (en) 2003-03-14 2004-03-15 Benzothiazole derivative compounds, compositions and uses

Publications (1)

Publication Number Publication Date
CY1113334T1 true CY1113334T1 (el) 2015-12-09

Family

ID=35057877

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20121101106T CY1113334T1 (el) 2003-03-14 2012-11-16 Ενωσεις, συνθεσεις και χρησεις παραγωγων βενζοθειαζολης
CY2015007C CY2015007I1 (el) 2003-03-14 2015-03-04 Ενωσεις, συνθεσεις και χρησεις παραγωγων βενζοθειαζολης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2015007C CY2015007I1 (el) 2003-03-14 2015-03-04 Ενωσεις, συνθεσεις και χρησεις παραγωγων βενζοθειαζολης

Country Status (17)

Country Link
EP (1) EP1611115B1 (da)
JP (1) JP4875487B2 (da)
CN (2) CN102532055B (da)
AU (2) AU2004221897B2 (da)
BE (1) BE2015C005I2 (da)
BR (1) BRPI0408274B8 (da)
CY (2) CY1113334T1 (da)
DK (1) DK1611115T3 (da)
ES (1) ES2393921T3 (da)
FR (1) FR15C0005I2 (da)
HK (1) HK1086270A1 (da)
HU (1) HUS1500006I1 (da)
NO (3) NO330861B1 (da)
PL (1) PL1611115T3 (da)
PT (1) PT1611115E (da)
RU (1) RU2440995C2 (da)
SI (1) SI1611115T1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230375B1 (hu) * 2000-08-24 2016-03-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Tioflavin-származékok és alkalmazásuk az Alzheimer-kór diagnózisában és kezelésében
US7270800B2 (en) 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US20050261365A1 (en) * 2004-05-20 2005-11-24 The Scripps Research Institute Transthyretin stabilization
GB0516564D0 (en) * 2005-08-12 2005-09-21 Ge Healthcare Ltd Fluorination process
CA2675228A1 (en) * 2007-01-30 2008-07-07 Ge Healthcare Limited Tools for aiding in the diagnosis of neurodegenerative diseases
CN101293878B (zh) * 2007-04-25 2010-12-15 中国科学院上海应用物理研究所 苯并噻唑苯胺类化合物及其制备方法和应用
CA2731738A1 (en) * 2008-07-24 2010-01-28 Siemens Medical Solutions Usa, Inc. Imaging agents useful for identifying ad pathology
EP2338059B1 (en) * 2008-09-23 2015-04-08 WisTa Laboratories Ltd. Ligands for aggregated tau molecules
KR101770532B1 (ko) 2013-09-26 2017-08-22 에프. 호프만-라 로슈 아게 이미징 수단으로서의 이미다조[1,2-a]피리딘-7-아민
JP6260967B2 (ja) * 2013-11-06 2018-01-17 国立大学法人京都大学 放射性ヨウ素標識化合物、及び、これを含む放射性医薬
CN103613589B (zh) * 2013-11-29 2016-03-30 江苏华益科技有限公司 一种用于神经退行性疾病领域的新型pet显像剂前体及标准品的合成方法
JP2017528520A (ja) * 2014-08-29 2017-09-28 シーエイチディーアイ ファウンデーション，インコーポレーテッド ハンチントンタンパク質のイメージング用プローブ
CN109400615B (zh) * 2017-08-18 2021-07-16 上海交通大学医学院附属新华医院 一种靶向β-淀粉样蛋白的香豆素类化合物及其制备与应用
GR1009516B (el) * 2018-03-22 2019-05-02 Εκεφε Δημοκριτος Τρικαρβονυλο-συμπλοκα μεταλλων μεταπτωσεως με βενζο-ετεροκυκλικο παραγωγο του κυκλοπενταδιενυλικου ανιοντος με υψηλη διαπερατοτητα του αιματοεγκεφαλικου φραγμου για εφαρμογες στη διαγνωση και θεραπεια νοσων του κνς

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID22275A (id) * 1996-11-22 1999-09-23 Elan Pharm Inc Komposisi farmasi yang terdiri dari derivat asam amino n-(aril atau heteroaril) dan metode untuk menghambat pelepasan b-amiloid peptida dan atau sintesisnya dengan menggunakan senyawa tersebut
GB9919673D0 (en) * 1999-08-20 1999-10-20 Cancer Res Campaign Tech 2-Arlybenzazole compounds
HU230375B1 (hu) * 2000-08-24 2016-03-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Tioflavin-származékok és alkalmazásuk az Alzheimer-kór diagnózisában és kezelésében
JP2004524289A (ja) * 2000-12-22 2004-08-12 アストラゼネカ・アクチエボラーグ 治療化合物
EP1381604B1 (en) * 2001-04-23 2006-12-27 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents
GB0229686D0 (en) * 2002-12-20 2003-01-29 Amersham Plc Solid-phase fluorination of benzothiazoles

Also Published As

Publication number Publication date
AU2004221897A2 (en) 2004-09-30
RU2440995C2 (ru) 2012-01-27
AU2004221897A9 (en) 2009-08-20
NO330861B1 (no) 2011-08-01
CN102532055B (zh) 2016-05-11
CN1784392A (zh) 2006-06-07
NO20110980L (no) 2005-12-13
AU2004221897B2 (en) 2010-11-18
JP2006522104A (ja) 2006-09-28
JP4875487B2 (ja) 2012-02-15
CN102532055A (zh) 2012-07-04
AU2011200667A1 (en) 2011-03-10
RU2005131872A (ru) 2006-02-27
BRPI0408274B1 (pt) 2019-02-26
PL1611115T3 (pl) 2013-01-31
BRPI0408274B8 (pt) 2021-05-25
SI1611115T1 (sl) 2012-12-31
NO20054674D0 (no) 2005-10-11
BE2015C005I2 (da) 2023-03-07
NO2015005I2 (no) 2015-02-18
EP1611115A1 (en) 2006-01-04
PT1611115E (pt) 2012-12-07
AU2004221897A1 (en) 2004-09-30
HK1086270A1 (en) 2006-09-15
NO20054674L (no) 2005-12-13
FR15C0005I2 (fr) 2015-07-24
BRPI0408274A (pt) 2006-03-21
EP1611115B1 (en) 2012-08-22
AU2011200667B2 (en) 2011-12-22
NO2015005I1 (no) 2015-03-02
ES2393921T3 (es) 2013-01-02
HUS1500006I1 (hu) 2015-02-18
DK1611115T3 (da) 2012-11-26
CY2015007I1 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
CY1113334T1 (el) Ενωσεις, συνθεσεις και χρησεις παραγωγων βενζοθειαζολης
CY1113311T1 (el) Παραγωγα θειοφλαβινης και η χρηση αυτων στην διαγνωση και θεραπεια της νοσου του αλτσχαϊμερ
CY1109724T1 (el) Θειαδιαζολιδινονες ως αναστολεις gsk-3
CY1125544T1 (el) Ενωσεις 1,2,4-οξαδιαζολοβενζοϊκου οξεος και η χρηση τους για μη νοηματικη καταστολη και στη θεραπευτικη αγωγη ασθενειας
CY1123050T1 (el) Φαρμακα ινδολιδονης για την θεραπεια ή προληψη ινωτικων ασθενειων
CY1108183T1 (el) Θειαζολυλο-διυδρο-ινδαζολια
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
BRPI0416361A (pt) métodos para regular a quantidade de isoforma 4 de apoe na corrente sanguìnea e/ou cérebro do paciente, para prevenir, tratar ou melhorar os sintomas do mal de alzheimer, para regular a produção de pelo menos um peptìdeos beta amilóide de um paciente ou regular um nìvel de pelo menos um peptìdeo beta amilóide na corrente sangüìnea e/ou cérebro de um paciente, para prevenir ou tratar um tumor associado com o colesterol, e para prevenir ou diminuir a incidência de xantomas em um paciente
CY1105922T1 (el) Χρηση υποκατεστημενων παραγωγων αζετιδινονης στη θepαπεια ασθενειας alzheimer
CY1108514T1 (el) Παραγωγα 1-φαινυλαλκανεκαρβοξυλικου οξεος για τη θεραπεια νευρογενων ασθενειων
SI1511710T1 (sl) Spojine, sestavki in postopki za zdravljenje amiloidnih bolezni in sinukleinopatij, kot je Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsova bolezen
CY1116119T1 (el) Παραγωγα ισοξαζολο-πυριδινης
CY1108347T1 (el) Ενωσεις ιμιδαζολιου για την θεραπεια νευροεκφυλιστικων διαταραχων
EA200501713A1 (ru) Фенилзамещённые карбоновые кислоты
ATE478082T1 (de) Phosphonate, monophosphonamidate, bisphosphonamidate zur behandlung von virenerkrankungen
EA200401114A2 (ru) Замещённые гидроксиэтиламины
NO20052580D0 (no) Blandinger for behandling av infeksjon av Flavivirida viruser
CY1109370T1 (el) Παραγωγα οξαδιαζολονης ως ppar δελτα αγωνιστες
ATE548032T1 (de) Verwendung von chlorguanabenzderivaten zur behandlung von mit polyglutaminexpansion assoziierten erkrankungen
DE602005004416D1 (de) Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit
DE602004016010D1 (de) Verfahren zur ä11cü-radiomarkierung von phenthiazin und phenothiazinartige verbindungen
BR0011728A (pt) Método de inibir a agregação de proteìna amilóide e imagem de depósitos de amilóide
DE602005021525D1 (de) R behandlung mit bucindolol
HUP9902796A2 (hu) Citokinek kialakulása inhibitorainak alkalmazása gyógyszerek előállítására, eljárás ezek azonosítására, valamint új imidazolszármazékok
CY1107243T1 (el) Ανταγωνιστες χημειοκινικων υποδοχεων και μεθοδοι χρησης τους